Allied Nevada Gold Corp (ANV) is at a 52-week low of $9.32 (high was $41.02). According to the GuruFocus Value Screen for 52-week lows, ANV is 77.3% off high, but several billionaire investor Gurus are holding this company, and Mario Gabelli and Chuck Royce traded ANV in the first quarter. Check out other Gurus holding ANV.
Compared to its first quarter of 2012, ANV’s net revenues increased 25% in the first quarter of 2013 to $49.2 million, but net income decreased 27% to $8.8 million, offset partially by lower gold and silver prices.
Down 64% over 12 months, Allied Nevada Gold has already mined 9,587 tons of ore in the first quarter of 2013, compared to 4,008 tons in the same period a year ago.
The company has a market cap of $873.6 million and trades at a P/E of 17.90 and a P/S of 3.90.
ANV expects to sell approximately 225,000 to 250,000 ounces of gold and 1.5 million to 1.8 million ounces of silver in 2013. Sales in the first half of the year are expected to be approximately 90,000 to100, 000 ounces of gold, increasing in the second half of the year.
ANV data by GuruFocus.com
The GuruFocus 52-week low screener reveals that ZIOPHARM Oncology Inc. (ZIOP) is also at a 52-week low of $1.63 (high was $6.33). According to the GuruFocus, ZIOP is 74.2% off high.
At least one Guru is holding: Jean-Marie Eveillard made a new buy in first quarter for 200,000 shares, buying at $1.63 per share. He owns 0.24% of shares outstanding.
Down 63% over 12 months, ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. The company is currently researching and evaluating seven compounds for the treatment of breast cancer, lung cancer and treatment of tumors. The company has a market cap of $140.3 million and a P/S 166.90.
Several days ago ZIOPHARM reported a GAAP net loss of $12.8 million for the first quarter of 2013, or $(0.15) per share, compared to a GAAP net loss of $24.5 million, or $(0.32) per share, in the first quarter of 2012. Excluding non-cash income of $10.8 million attributable to the change in liability-classified warrants, Non-GAAP net loss was $23.6 million, or $(0.28) per share, for the quarter ended March 31, 2013. In comparison, Non-GAAP net loss for the first quarter of 2012 was $18.7 million, or $(0.25) per share, which excludes a non-cash loss of $5.8 million attributable to the change in liability-classified warrants, the company reported.
ZIOP data by GuruFocus.com
The GuruFocus 52-week low screener also shows that Brazil's Centrais Electrics Brasileiras S.A. (EBR) is at a 52-week low of $2.40 (high was $8.37). According to the GuruFocus, EBR is 71.32% off high.
Down 71% over 12 months, the company has a market cap of $3.3 billion and trades at a P/E of 1.90 and a P/S of 0.19.
Three Gurus are holding EBR: Jim Simons, Jeremy Grantham, and Charles Brandes. Check here for Guru ownership details.
Centrais Electrics Brasileiras S.A. (EBR) is an electric utilities company, partly owned by Brazil’s federal government with a 52% stake. EBR specializes in the development, financing, construction and operation of electric power plants, as well as nuclear, hydroelectric and fossil fuel electric power projects.
EBR posted a $3.4 billion loss in 2012, and last month announced that it expects a finance package from state-run lenders for a $2.5 billion line of credit by June 2013, according to Reuters.
EBR data by GuruFocus.com
The GuruFocus 52-week low screener also shows that Idenix Pharmaceuticals Inc. (IDIX) is at a 52-week low of $3.53 (high was $11.3). IDIX is 68.8% off high. The company has a market cap of $489 million and trades at a P/S of 13.20.
Three Gurus are still holding this company that has eight new drug candidates in the pipeline. Seth Klarman is the largest stakeholder with 24.7 million shares. Check here for more Guru ownership details.
Down 57% over 12 months, Idenix is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. The company's main focus is on the treatment of hepatitis C virus, or HCV, a cause of liver disease.
For the first quarter of 2013, Idenix reported total revenues of $0.9 million, compared to total revenues of $35.6 million in the first quarter of 2012. The company reported a net loss of $30.8 million, or ($0.23) per basic and diluted share, for the first quarter ended March 31, 2013, compared to a net income of $11.4 million, or $0.11 per basic share and $0.10 per diluted share for the first quarter ended March 31, 2012. As of that same quarter ending, Idenix's cash and cash equivalents totaled $205.3 million.
IDIX data by GuruFocus.com
If you are not yet a Premium Member, we invite you for a 7-day Free Trial.
Check out the GuruFocus special feature 52-week low screener. This special feature helps you find the stocks hitting new lows but are still held by top investor Gurus and Insiders.
Also check out:
- Charles Brandes Undervalued Stocks
- Charles Brandes Top Growth Companies
- Charles Brandes High Yield stocks, and
- Stocks that Charles Brandes keeps buying
- Jean-Marie Eveillard Undervalued Stocks
- Jean-Marie Eveillard Top Growth Companies
- Jean-Marie Eveillard High Yield stocks, and
- Stocks that Jean-Marie Eveillard keeps buying